Novo Nordisk A/S (NYSE:NVO) is one of the Best Bargain Stocks to Buy in November. On October 22, Reuters reported that Novo Nordisk A/S (NYSE:NVO)’s top investor, the non-profit Novo Nordisk Foundation,

Wegovy Zepbound cost-effectiveness report finds both drugs remain valuable at higher prices despite affordability concerns, per ICER analysis.

The Novo Nordisk Foundation owns 28.1% of the company's shares, but holds a three-quarter share of the voting rights, which indicates that it holds a lot of sway with how the company is run and who holds senior roles. The Foundation successfully pushed for the removal of former chief executive Lars Fruergaard Jorgensen in May.

The chairman of Novo Nordisk and six other independent board members quit on Tuesday after a dispute with the company's controlling shareholder, as the drugmaker looks to revive sales of its blockbuster weight-loss drug Wegovy.

Novo Nordisk, which lobbied to win Medicaid reimbursement for its obesity drug Wegovy, is fighting to keep that coverage as some U.S. states struggle with the treatment's costs.

Novo Nordisk (NVO) recruits top healthcare analyst Michael Novod, a long time bull of the company, as head of its investor relations department. Read more here.

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030.

Novo Nordisk today announced plans to present 11 abstracts at the 76th Annual American Association for the Study of Liver Diseases (AASLD) congress, The Liver Meeting® 2025, from 7 to 11 November in Washington D.